Acetyl-HSPA1A (K246) Antibody

Basic Research Questions

• What is Acetyl-HSPA1A (K246) Antibody and what is its target specificity?

  Acetyl-HSPA1A (K246) Antibody is a rabbit polyclonal antibody that specifically recognizes the acetylated form of HSPA1A (Heat Shock Protein 70 kDa Family A Member 1A) at lysine 246. This antibody is designed to detect post-translational acetylation modifications at a specific lysine residue within the internal region of the human HSP70 protein . The antibody has been developed using a synthesized acetyl-peptide derived from the internal region of human HSP70 around the acetylation site of K246 . It demonstrates specific reactivity with human samples, though cross-reactivity with mouse and rat HSP70 has also been observed in some formulations . This specificity makes it a valuable tool for studying acetylation-dependent functions of HSPA1A in cellular stress responses and other biological processes.

• What experimental applications is Acetyl-HSPA1A (K246) Antibody validated for?

  Acetyl-HSPA1A (K246) Antibody has been validated for several key laboratory applications:

  Application	Recommended Dilution	Validation Status
  Western Blot (WB)	1:500 - 1:2000	Validated
  ELISA	1:10000	Validated
  Immunohistochemistry (IHC)	Not specified	Not fully validated
  Immunofluorescence (IF)	Not specified	Not fully validated

  The antibody performs optimally in Western blot applications for detecting acetylated HSPA1A in cell lysates and tissue samples . For Western blotting, researchers should optimize dilutions based on their specific experimental conditions and detection methods. The antibody's high sensitivity in ELISA makes it suitable for quantitative measurements of acetylated HSPA1A levels in complex biological samples .

• How does acetylation at K246 affect HSPA1A function and interactions?

  Acetylation at lysine 246 (K246) represents a significant post-translational modification that regulates HSPA1A functionality in several ways:

  • Chaperone Activity Modulation: K246 acetylation can alter the protein folding capacity of HSPA1A by modifying its interaction with client proteins and co-chaperones .

  • Protein-Protein Interaction Regulation: This specific acetylation can influence HSPA1A's ability to interact with other cellular proteins, including those involved in the ubiquitin-proteasome pathway .

  • Subcellular Localization: K246 acetylation may contribute to HSPA1A's distribution between cytoplasmic and membrane-associated pools. Research indicates that post-translational modifications influence HSPA1A's plasma membrane localization, which is particularly relevant in stressed and tumor cells .

  • Immunomodulatory Functions: The acetylation status at K246 may regulate HSPA1A's interaction with toll-like receptors (TLRs), affecting cytokine secretion and immune responses. Studies have shown that HSPA1A interacts with TLR2, TLR4, TLR5, and TLR7 on differentiated U937 monocytic cells, influencing the secretion of cytokines such as TNF-α, IL-1β, and IL-10 .

• What is the relationship between HSPA1A and cardiovascular disease?

  HSPA1A has been implicated in cardiovascular health and disease through multiple mechanisms:

  • Serum Biomarker: Studies have shown that atherosclerotic subjects exhibit significantly lower circulating HSPA1A levels compared to individuals without atherosclerosis, suggesting its potential as a biomarker for cardiovascular disease .

  • Genetic Polymorphisms: Two single nucleotide polymorphisms (SNPs) in the HSPA1A gene (db rs1008438 -110A/C and db rs1043618 +190 G/C) have been associated with differential HSPA1A production. The CC genotype for both polymorphisms correlates with significantly lower intragranulocytic HSPA1A levels compared to other genotypes .

  • Protective Functions: HSPA1A has antiapoptotic and antithrombotic properties that may protect against atherosclerosis development. Research indicates that the -110A and +190 G alleles could potentially serve as genetic biomarkers for a less severe clinical phenotype regarding the risk of developing atherosclerosis .

  • Inflammatory Modulation: HSPA1A exhibits anti-inflammatory properties by inhibiting the expression of proinflammatory cytokines and transcription factors like nuclear factor kappa-B (NF-κB). Lower levels of intracellular and circulating HSPA1A may promote a proinflammatory state, increasing the vulnerability of arterial walls to damage from vascular risk factors .

Advanced Research Questions

• What methodological considerations should researchers apply when using Acetyl-HSPA1A (K246) Antibody in heat shock response studies?

  When investigating heat shock responses using the Acetyl-HSPA1A (K246) Antibody, researchers should consider several methodological factors:

  • Heat Shock Protocols: Standardize heat shock conditions (temperature, duration, recovery time) based on cell type. Typical protocols involve exposing cells to 42-45°C for 30-60 minutes followed by recovery at 37°C .

  • Acetylation Dynamics: Monitor the temporal changes in K246 acetylation following heat shock. Design time-course experiments (0, 1, 3, 6, 12, 24 hours post-shock) to capture acetylation dynamics .

  • Subcellular Fractionation: Implement proper fractionation techniques to separate cytosolic, nuclear, and membrane-bound HSPA1A pools. This is particularly important as HSPA1A's localization changes during stress responses .

  • Controls and Validation:

    • Include non-heat shocked samples as negative controls

    • Use pan-HSPA1A antibodies in parallel to determine total protein levels

    • Consider using HDAC inhibitors (e.g., trichostatin A) to maximize acetylation signal

    • Include HSPA1A knockdown or knockout samples as specificity controls

  • Protein Extraction Considerations: Use extraction buffers containing deacetylase inhibitors (e.g., nicotinamide, trichostatin A) to preserve the acetylation state. Avoid harsh detergents that might affect antibody recognition of the acetylated epitope .

• How can Acetyl-HSPA1A (K246) Antibody be utilized to investigate the relationship between HSPA1A acetylation and membrane localization?

  To study the relationship between K246 acetylation and HSPA1A membrane localization, researchers can employ the following methodological approach:

  1. Cell Surface Biotinylation: Perform cell surface biotinylation followed by streptavidin pull-down and Western blot analysis with the Acetyl-HSPA1A (K246) Antibody to quantify acetylated HSPA1A at the plasma membrane .

  2. Lipid Manipulation Experiments: Manipulate cellular lipid content using compounds such as:

     • Ionomycin (calcium ionophore)

     • Phenyl arsine oxide (PAO, PI4K inhibitor)

     • GSK-A1 (PI4K inhibitor)

     • Wortmannin (PI3K inhibitor)
       Then analyze changes in acetylated HSPA1A membrane localization .

  3. Co-localization Studies: Perform immunofluorescence co-localization studies using:

     • Acetyl-HSPA1A (K246) Antibody

     • Membrane markers (e.g., Na+/K+ ATPase)

     • Lipid probes (e.g., fluorescently labeled phosphoinositides)
       Analyze using confocal microscopy and quantitative co-localization metrics .

  4. Rapamycin-Induced Phosphatase System: Employ the rapamycin-induced phosphatase system to selectively deplete specific phospholipids (PI(4)P and PI(4,5)P2) and observe effects on acetylated HSPA1A membrane localization .

  5. Lipid Biosensor Co-expression: Co-express HSPA1A with lipid biosensors masking PI(4)P and PI(3)P, then quantify the effects on acetylated HSPA1A surface presentation using the Acetyl-HSPA1A (K246) Antibody .

• What technical approaches can be used to assess the impact of K246 acetylation on HSPA1A's chaperone function?

  To evaluate how K246 acetylation affects HSPA1A's chaperone activity, researchers can implement these advanced technical approaches:

  1. Protein Aggregation Assays: Compare the ability of acetylated and non-acetylated HSPA1A to prevent aggregation of model substrates such as citrate synthase or luciferase under heat stress. Measure aggregation spectrophotometrically at 320-340 nm .

  2. Client Protein Binding Affinity Analysis: Use surface plasmon resonance (SPR) or microscale thermophoresis (MST) to quantitatively measure binding affinity differences between acetylated and non-acetylated HSPA1A for client proteins .

  3. ATP Hydrolysis Assays: Measure the ATPase activity of acetylated versus non-acetylated HSPA1A using malachite green phosphate assays to determine if K246 acetylation alters the rate of ATP hydrolysis, which is essential for chaperone cycling .

  4. Site-Directed Mutagenesis Approaches: Generate K246R (cannot be acetylated) and K246Q (acetylation mimetic) mutants of HSPA1A and compare their chaperone activities in cell-based and in vitro assays .

  5. Protein Refolding Assays: Assess the ability of acetylated and non-acetylated HSPA1A to refold denatured substrates (e.g., firefly luciferase) by measuring the recovery of substrate activity over time .

  6. Co-chaperone Interaction Studies: Use co-immunoprecipitation with the Acetyl-HSPA1A (K246) Antibody followed by mass spectrometry to identify differential co-chaperone interactions based on K246 acetylation status .

• How can Acetyl-HSPA1A (K246) Antibody be used to study the relationship between HSPA1A acetylation and toll-like receptor signaling?

  To investigate the relationship between HSPA1A acetylation at K246 and toll-like receptor (TLR) signaling, researchers can implement the following methodological approach:

  1. Flow Cytometry Analysis: Treat differentiated U937 monocytic cells (or other immune cells) with recombinant HSPA1A, then immunostain with:

     • Acetyl-HSPA1A (K246) Antibody

     • Anti-TLR2, Anti-TLR4, Anti-TLR5, or Anti-TLR7 antibodies
       Analyze co-expression patterns using flow cytometry .

  2. Cytokine Secretion Assays: Measure secretion of TNF-α, IL-1β, and IL-10 in response to treatment with acetylated versus non-acetylated HSPA1A using ELISA. The experimental design should include:

     Treatment Condition	Expected TNF-α (pg/ml)	Expected IL-1β (pg/ml)
     Control (no treatment)	Baseline	Baseline
     HSPA1A (non-acetylated)	~600	~300
     HSPA1A + TLR2 blocking	~400 (↓33%)	~125 (↓58%)
     Acetylated HSPA1A	To be determined	To be determined
     Acetylated HSPA1A + TLR2 blocking	To be determined	To be determined

     These values are based on similar experiments reported in the literature .

  3. Co-immunoprecipitation Studies: Use the Acetyl-HSPA1A (K246) Antibody to immunoprecipitate acetylated HSPA1A, then probe for associated TLRs using Western blot analysis .

  4. TLR Blocking Peptide Experiments: Pre-incubate cells with TLR-specific blocking peptides, then treat with acetylated HSPA1A and measure changes in downstream signaling (e.g., NF-κB activation) and cytokine production .

  5. Microscopic Co-localization: Perform immunofluorescence microscopy using:

     • Acetyl-HSPA1A (K246) Antibody

     • Fluorescently labeled anti-TLR antibodies
       Analyze co-localization at the plasma membrane and in endosomal compartments .

• What are the optimal conditions for detecting acetylated HSPA1A at K246 in complex biological samples?

  For optimal detection of acetylated HSPA1A at K246 in complex biological samples, researchers should consider these critical parameters:

  1. Sample Preparation:

     • For cell lysates: Use RIPA buffer supplemented with protease inhibitors and deacetylase inhibitors (10 mM nicotinamide, 1 μM trichostatin A) .

     • For tissue samples: Homogenize in ice-cold RIPA buffer with inhibitors, followed by sonication (3 × 10s pulses at 30% amplitude) .

     • For serum/plasma: Dilute 1:5 in PBS before analysis .

  2. Protein Concentration Determination:

     • Use the Lowry or BCA assay method rather than Bradford, as the latter can be affected by detergents present in lysis buffers .

     • Standardize protein loading to 20-50 μg per lane for Western blot .

  3. Western Blot Optimization:

     • Transfer conditions: 100V for 60 minutes or 30V overnight at 4°C for efficient transfer of the 70 kDa protein .

     • Blocking: 5% BSA in TBST is preferable to milk, which contains endogenous bioactive compounds that may interfere with detection .

     • Primary antibody incubation: 1:1000 dilution, overnight at 4°C .

     • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:5000, room temperature for 1 hour .

     • Enhanced chemiluminescence detection with exposure times of 30 seconds to 5 minutes .

  4. ELISA Considerations:

     • Follow sandwich ELISA protocols using capture antibodies against total HSPA1A and detection with Acetyl-HSPA1A (K246) Antibody .

     • Optimal antibody dilution: 1:10000 for highest specificity .

     • Include standard curves using recombinant acetylated HSPA1A when available.

• How can Acetyl-HSPA1A (K246) Antibody be used to investigate the relationship between HSPA1A acetylation and genetic polymorphisms in disease models?

  To study the relationship between HSPA1A acetylation at K246 and genetic polymorphisms in disease contexts, researchers can implement this comprehensive methodology:

  1. Genotyping Strategy:

     • Perform direct Sanger sequencing of the regulatory region of the HSPA1A gene, focusing on two key SNPs: -110A/C (dbSNP rs1008438) in the core promoter region and +190 G/C (dbSNP rs1043618) in the 5′UTR region .

     • Design PCR primers targeting a ~1,053-bp sequence comprising the promoter, 5′UTR region, and part of the HSPA1A gene .

     Polymorphism	Position	dbSNP ID	Functional Region
     -110A/C	Promoter	rs1008438	Core promoter
     +190 G/C	5′UTR	rs1043618	5′ untranslated region

  2. Stratification of Study Population:

     • Categorize subjects based on vascular risk factors:

       • Group 0: No vascular risk factor or risk <5%

       • Group 1: Moderate vascular risk (10-20%) without clinical cardiovascular disease

       • Group 2: Subjects with established atherosclerotic disease

  3. Quantification of Acetylated HSPA1A:

     • Measure serum and intragranulocytic levels of acetylated HSPA1A using the Acetyl-HSPA1A (K246) Antibody in ELISA or Western blot applications .

     • For quantitative analysis of intragranulocytic HSPA1A:

       • Isolate polymorphonuclear leukocytes (PMNs) using density gradient centrifugation

       • Lyse cells in RIPA buffer with protease and phosphatase inhibitors

       • Homogenize and quantify protein concentration using the Lowry microassay method

       • Normalize results to total protein content (ng HSPA1A/μg total protein)

  4. Correlation Analysis:

     • Analyze the relationship between genotype (AA, AC, CC for -110A/C and GG, GC, CC for +190 G/C), acetylation levels at K246, and disease status .

     • Perform statistical analysis using one-way ANOVA with Bonferroni's multiple comparison post hoc test .

  5. Functional Validation:

     • Conduct in vitro reporter gene assays to evaluate how different genotypes affect HSPA1A promoter activity and subsequent protein expression and acetylation .

     • Use site-directed mutagenesis to create constructs representing the different allelic variants and measure their impact on HSPA1A expression and acetylation levels .